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Penicillin-resistant pneumococci-implications for 
management of community-acquired pneumonia and 
meningitis 
Hisham M. Ziglam and Roger G. Finchc2) 
Penicillin-nonsusceptible Streptococcus pneumoniae isolates have become increasingly prevalent worldwide. They 
are well-known agents of community-acquired infections such as otitis media, pneumonia and bacterial meningitis. 
Therapy of pneumococcal infections is made difficult by the emergence and spread of bacterial resistance to penicillin 
and other beta-lactams, as well as other antimicrobials such as macrolides. This article reviews current concepts of 
epidemiology and the implications of penicillin-nonsusceptible pneumococci for management of community- 
acquired pneumonia and meningitis. 
Int J Infect Dis 2002; 6: 514420 
Streptococcus pneumoniae is the most common cause of 
pyogenic meningitis, community-acquired pneumonia, 
and acute otitis media. Mortality and suppurative com- 
plications associated with pneumococcal infections 
decreased dramatically following the introduction of 
penicillin therapy in the 1940s. However, pneumococcal 
strains with decreased susceptibility to penicillin were 
identified in Australia and Papua/New Guinea in the 
196O~l,~ and subsequently South Africa in the 1970~,~ 
where they were associated with failures of therapy in 
patients with meningitis. Isolates which were inter- 
mediately resistant (minimal inhibitory concentration 
(MIC) 0.1-1.0 pg/mL) or resistant (MIC=2.0 pg/mL) to 
penicillin became increasingly prevalent worldwide 
during the 1980s. Multidrug resistance also appeared. 
The clinical impact of pneumococcal resistance varies 
according to the site of infection, largely reflecting the 
degree of antibiotic penetration to that site, and the 
ability of the host immune response to clear the 
infection. Pneumococcal resistance has led to treatment 
failures in patients with meningitis and acute otitis 
media4. The impact of pneumococcal resistance on the 
treatment of pneumonia has been more difficult to 
determine,5 although there is recent evidence that 
increased morbidity and mortality are associated with 
high-level beta-lactam resistance.6 
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EPIDEMIOLOGY OF PENICILLIN-RESISTANT 
PNEUMOCOCCI 
Drug resistance among pneumococci is not a recent 
phenomenon. In 1943, pneumococcal isolates resistant 
to sulfonamides were reported. However, the first report 
describing a penicillin-resistant S. pneumoniae (PRSP) 
isolate (MIC=0.6 pg/mL) was from Australia in 1967, 
followed by an isolate with a penicillin MIC of 0.5 
pg/mL isolated in New Guinea in 1969. By 1974, the 
prevalence of PRSP in Australia and New Guinea 
approached 12%. However, the first major report of the 
significant health impact of penicillin resistance was in 
1977, from South Africa, among S. pneumoniae, where 
epidemic pneumococcal meningitis occurred with 
clearly resistant strains (MICs of 4-8 pg/mL). Since then, 
the frequency of PRSP has been increasing throughout 
the world. 
The rate at which PRSP are emerging is alarming. 
There has been a 60-fold increase in the number of 
resistant isolates, including >20 different serotypes, 
during the past 5-7 years. 7 The overall incidence of 
PRSP in the USA has increased from ~5% before 1989 
to 6.6% in 1991 to 33% in 1997.8,9 Similar trends have 
been observed in other countries. The overall prevalence 
of PRSP from Canadian laboratories was 21.2%.l” In 
Spain, penicillin resistance increased sharply until 
1989,11 but it has since remained stable, with a resistance 
rate among invasive pneumococci of about 42%. In 
many countries with low resistance rates during the 
previous decade, there has been a remarkable increase 
in the 199Os, similar to that which occurred in Spain in 
the 1980s. In France it increased from 3.2% in 1987 to 
43% in 1999. In contrast, the incidence of PRSP has 
remained stable at relatively low levels in other areas of 
Europe: Denmark, 0.1%; Germany, 1.8%; Belgium, 
24%;Sweden, 1.7%;Finland, 1.7%; and Italy,5.5%.12J3 
In the UK, resistance rates among isolates referred to 
the PHLS increased from 1.5% to 8.9% in 2000. 
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The pneumococcal serotypes most commonly 
associated with penicillin resistance are those most often 
responsible for infection and carriage in children, 
namely 6,14,19 and 23E14 The most widespread of these 
is often referred to in the literature as the Spanish/USA 
serotype 23F clone. Isolates belonging to this clone are 
resistant to penicillin, tetracycline, and chloramphenicol, 
and often to macrolides, trimethoprim and sulfametho- 
xazole as well. The Spanish/USA clone was identified as 
a major component of the penicillin-resistant pneumo- 
coccal flora in countries on five continents. Pneumococci 
belonging to this clone are not only geographically wide- 
spread but also represent a considerable proportion of 
penicillin-resistant pneumococci in a given epidemio- 
logical setting. 
However, it is difficult to explain how the Spanish 
clones 6B and 23F have spread to and become estab- 
lished in regions as remote as Iceland or South Koreai 
but have not become prevalent in the UK or Germany, 
in spite of major tourism between these countries. 
Likewise, the Spanish clone 6B was detected in Icelandi 
and Finland simultaneously, yet, surprisingly, the 
epidemic spread of clone 6B took place in Iceland but 
not in Finland. 
Some circulating resistant clones, such as the 
multidrug-resistant serotype 19F, are variants of the 
Spanish 23F clone which arose from horizontal transfer 
of capsular genes. I6 Other clones have emerged as result 
of horizontal spread of altered penicillin-binding protein 
pbp genes (e.g. the penicillin-resistant serotype 9V 
clone). r7,18 Although clonal spread, horizontal transfer 
and antibiotic policy seem to have a definitive influence 
on PRP prevalence, there are many aspects of the 
epidemiology that are not easily explained. 
Six serotypes (i.e. 6A, 6B, 9, 14, 19F, and 23F) 
account for more than 80% of resistant isolates. These 
serotypes are all represented in the currently available 
pneumococcal polysaccharide vaccines. The new 
pneumococcal conjugate vaccine in which purified poly- 
saccharides of the epidemiologically most important 
serotypes are conjugated to a carrier protein has 
recently been developed, and its impact on pneumo- 
coccal lower respiratory tract infections will be awaited 
with interest. Serotypes 1,3,4,5,7,11,15 and 18 rarely 
carry antibiotic resistance genes. 
MECHANISM OF ANTIMICROBIAL 
RESISTANCE 
Penicillin resistance is a result of gene mutations that 
lead to alterations in penicillin-binding proteins (PBPs). 
Alteration of PBPs decreases binding of penicillin and 
other beta-lactam antibiotics, including cephalosporins, 
to bacterial targets. Antibiotic resistance is a stepwise 
process, with successive mutations resulting in increasing 
resistance. Resistance is not dependent on beta- 
lactamases; thus, beta-lactambeta-lactamase inhibitor 
combinations (e.g. amoxicillin/clavulanate) are no more 
effective than beta-lactam antibiotics alone. Even 
though mechanisms of resistance differ, rates of resis- 
tance to non-beta-lactam antimicrobials are higher in 
penicillin-resistant strains. Resistance to non-beta- 
lactam antibiotics may be acquired through several 
mechanisms: transformation, in which free DNA 
encoding alterations is acquired from other bacteria by 
pneumococci and incorporated into their own DNA 
(e.g. from the viridans group streptococci); transposons 
mediated; spontaneous mutations due to selection 
pressure. All can result in all beta-lactam antimicrobials 
having decreased binding affinity for PBPs. Recently, 
new types of modification of PBPs corresponding to 
resistance to broad-spectrum penicillins (e.g. PBP2b, 
resulting in greater resistance to piperacillin) and 
cephalosporins (e.g. PBP2x, resulting in greater 
resistance to cefotaxime) have been discovered.19 
Risk factors for carriage or infection with resistant 
pneumococcal strains include prior antibiotic use,2o age 
less than 5 years,21J2 attendance at daycare centers,23 
and severe underlying disease including hematological 
malignancy and human immunodeficiency virus infec- 
tion.24 Resistant isolates are more commonly isolated 
from the middle ear and paransasal sinuses. 
Recent studies have found a higher rate of recovery 
of antibiotic-resistant pneumococci from HIV-infected 
patients. Alcoholism and age >65 years are also 
associated with an increased risk. Some of the same risk 
factors in children apply to adults, particularly with 
regard to cohorting and recent antibiotic use. Pallares et 
al demonstrated that recent antibiotic use and hospital- 
ization are important clues to a potential drug-resistant 
infection.25 Interestingly, resistance is reported less com- 
monly among invasive organisms than in those from 
upper airway colonization or infection. This may be 
explained in part by bias in sampling, as otitis and 
sinusitis are usually treated empirically without obtain- 
ing a culture until primary treatment has failed. Middle 
ear and sinus isolates are thus more likely to have been 
exposed to repeated courses of antibiotics. Noninvasive 
strains in the upper airway also have prolonged contact 
with the viridans streptococci thought to be the reservoir 
of resistance genes. 
MANAGEMENT OF SERIOUS INFECTIONS 
Meningitis 
Following the reports of treatment failures caused by 
pneumococcal isolates with decreased susceptibility to 
penicillin in the 1970s pneumococci with penicillin 
MICs between 0.1 and 1.0 mg/L became increasingly 
associated with microbiological and/or clinical treat- 
ment failures in patients with pneumococcal meningitis. 
For treatment to be successful, cerebrospinal fluid (CSF) 
concentrations need to be lo-loo-fold higher than the 
MIC. Penicillin does not routinely achieve adequate 
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levels in the CSF (CSF peak concentrations need to be 
about 1.0 mg/L to reliably treat meningitis caused by 
intermediately susceptible strains (penicillin MIC 
0.1-1.0 mg/L)). 
By the mid-1980s the third-generation cephalo- 
sporins ceftriaxone and cefotaxime were widely used in 
the empirical treatment of suspected bacterial menin- 
gitis in childhood. S. pneumoniae isolates were initially 
uniformly susceptible to these cephalosporins. However, 
by the early 1990s as penicillin-resistant pneumococcal 
isolates became more widespread, treatment failures 
associated with strains of reduced susceptibility to 
cefotaxime or ceftriaxone were also reported. 
Vancomycin has been increasingly used in the 
treatment of pneumococcal meningitis resistant to 
penicillin and chloramphenicol, and when high-dose 
cephalosporins have failed.26 CSF concentrations are 
increased in the presence of inflammation. The simul- 
taneous use of dexamethasone is known to reduce 
CSF concentrations.27 Vancomycin may also have a 
place in combination with cephalosporins when 
diminished susceptibility to the cephalosporin has been 
demonstrated.28 
Optimal therapy for meningitis caused by PRSP is 
still not established. Several options are available and 
should be selected on the basis of the local epidemiology 
of resistance when this is known. Where the majority of 
isolates remain sensitive to penicillin, this drug can 
continue to be used, although for empirical therapy, 
ceftriaxone is a more reliable choice. Where resistance 
rates are high, it seems prudent to treat all patients with 
purulent meningitis empirically with vancomycin 
combined with either cefotaxime or ceftriaxone while 
awaiting CSF culture and antimicrobial susceptibility 
test results. Alternative regimens for penicillin and 
cephalosporin-resistant pneumococcal meningitis 
include: rifampicin with either ceftriaxone or cefo- 
taxime; rifampicin and vancomycin; and vancomycin 
combined with chloramphenicol. Cefepime, a broad- 
spectrum cephalosporin, and meropenem, a carbapenem 
antibiotic, have both been evaluated in clinical trials for 
the treatment of bacterial meningitis. However, no 
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penicillin-resistant pneumococci were included in the 
published studies, and the efficacy of cefepime in 
treating PRSP meningitis remains to be established. 
In summary, the initial treatment of suspected 
pneumococcal meningitis should be altered, especially 
in areas where resistant pneumococci are regularly 
encountered. Initial therapy with cefotaxime or 
ceftriaxone combined with vancomycin is recom- 
mended. Once the results of culture and susceptibility 
testing are available, modifications of therapy should be 
made. If the strain is susceptible to penicillin, cefotaxime 
or ceftriaxone, vancomycin should be discontinued. 
Vancomycin plus cefotaxime or ceftriaxone should be 
used only if the organism is either intermediately or 
highly resistant to both penicillin and the cephalo- 
sporins. The addition of rifampicin or substitution of 
rifampicin for vancomycin after 24-48 h could be 
considered if the organism is susceptible to rifampicin or 
where there is evidence of an inadequate clinical or 
bacteriological response, or when dexamethasone has 
been used in the initial management. It is prudent to 
perform a repeat CSF examination and culture at 
24-48 h, until greater experience is gained in treating 
meningitis caused by PRP. 
Pneumonia 
Pneumonia is the most serious of the lower respiratory 
tract infections. Community-acquired pneumonia 
(CAP) has an incidence of l-3/1000, and approximately 
20-42% of cases require hospitalization. One of the 
most important factors affecting outcome for patients 
with pneumonia is the prompt prescribing of appro- 
priate antimicrobial therapy. Unfortunately, despite 
extensive diagnostic testing, a causative agent is 
identified in about 25% of routinely managed pneu- 
monia cases, rising to about 50% in published studies, in 
which every effort is made to establish the diagnosis. 
S. pneumoniae is the most common cause of CAP 
and is also responsible for a number of cases of hospital- 
acquired pneumonia (HAP), especially early-onset 
infections. Efforts should be made to establish the 
Table 2. Recommended empirical regimens for treating CAP in relation to the prevalence of drug-resistant 5. pneumoniae 
Empirical treatment 
Outpatients 
Macrolide 
Doxycycline 
Oral p-lactam 
Fluoroquinolone 
Hospitalized (non-ICLJ) patients 
Parenteral beta-lactam+macrolides 
Fluoroquinolone 
Penicillin MIC (mglL) 
50.06 0.12-I 2 4 Comments 
+++ + + - Covers atypical pathogen 
+++ ++ + - Covers atypical pathogen, not suitable for children 
or pregnant women 
+++ ++ + - Does not cover atypical pathogens 
+++ +++ ++ ++ Not first line because of concern of resistance 
+++ +++ ++ + Cephalosporins have superior activity against 
resistant pneumococci in comparison with 
ampicillin/sulbactam 
+++ +++ +++ ++ Not first line because of concern of resistance 
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microbial etiology of all patients admitted to hospital 
with CAP and those developing HAP Blood and 
sputum cultures should ideally be collected before 
starting antibiotic therapy, which should not be delayed, 
particularly in those with severe infection. Contiguous 
or metastatic sites of infection such as pleural fluid, joint 
fluid or the central nervous system should also be 
cultured if involved. 
To date, no large studies have been performed to 
evaluate the role of sputum Gram stain or culture in the 
management of lower respiratory tract infections due to 
PRSP, much less to compare their diagnostic accuracy 
with that of ‘gold-standard’ investigations (i.e. culture of 
blood, transthoracic needle aspiration, or pleural fluid 
aspiration), since the sensitivity and specificity of 
sputum cultures continue to be questioned. Even if S. 
pneumoniae could be reliably identified by Gram stain, 
antimicrobial susceptibilities are dependent on sputum 
culture. 
The increasing incidence of PRSP has given rise to 
considerable concern and variations in the recommen- 
dations for initial empirical management of CAP 
Several recently published evidence-based guidelines 
have addressed the issue of PRSP, and yet the position 
of beta-lactam antibiotics and notably penicillin in the 
management of CAP differs considerably (Table 1). 
Macrolides and the new respiratory fluoroquinolones 
feature as recommended first-line therapy for patients 
managed in the community in North America. In the 
UK, amoxicillin remains the preferred agent for 
community-managed or non-severe hospital-managed 
infection. Macrolides are an alternative but are com- 
bined with a beta-lactam for those hospitalized and who 
have clearly failed community management. This 
combination extends the spectrum of activity to include 
Legionella spp. and atypical pathogens. 
For infections shown to be due to S. pneumoniae, it 
is recommended that local susceptibility patterns be 
considered, since penicillin-resistant pneumococci also 
often exhibit reduced susceptibility to macrolides. For 
hospitalized ward-managed patients, an extended- 
spectrum cephalosporin (cefotaxime or ceftriaxone) 
plus a macrolide, or a beta-lactam/beta-lactamase 
inhibitor combined with a macrolide or a fluoro- 
quinolone, are recommended. Fluoroquinolones are 
also preferred alternative therapy for patients in the 
intensive care unit with lung damage, aspiration or beta- 
lactam intolerance. 
In the era of increasing pneumococcal resistance, 
new recommendations for the management and 
surveillance of CAP were recently published in a con- 
sensus paper from the drug-resistant S. pneumoniae 
therapeutic working group (DRSPTWG) (Table 2).29 
The DRSPTWG recommends that pneumococcal 
infections should be considered susceptible if the 
penicillin MIC is no greater than 1 mg/L, of intermediate 
susceptibility if the MIC is 2 mg/L, and resistant if the 
MIC is 4 mg/L or greater. 
There have been few prospective studies looking at 
the impact of penicillin resistance on the outcome of 
pneumococcal pneumonia. In one study of 108 children 
with pneumococcal infections, 78 of whom had pneu- 
monia, the clinical success of antimicrobial therapy was 
similar for PRSP and PSSP infections. However, only 
one isolate was highly resistant to penicillin.30 Another 
study of 75 patients with pneumococcal pneumonia 
found no increase in mortality related to decreased 
penicillin susceptibility, although the MICs of isolates 
were not reported;31 similar results were reported from 
San Francisco.32 
The macrolide antimicrobials have been used 
successfully to treat respiratory infections for many 
decades. They have a broad spectrum of activity, 
providing coverage against key respiratory pathogens, 
including atypical/intracellular pathogens. However, 
erythromycin resistance among pneumococci is now a 
major concern. Pneumococcal macrolide resistance is 
usually expressed as one of two phenotypes. The first, 
known as M phenotype (mejE gene), produces moder- 
ate levels of macrolide resistance (MICs ~32 mg/L).33 A 
second phenotype, ML& (ermAM gene), is usually 
associated with very high-level macrolide resistance 
(MICs >64 mg/L).33 As a result of these in vitro reports, 
many prescribers are changing from macrolides to other 
agents, notably fluoroquinolones for pneumococcal 
infections, as well as for community-acquired respiratory 
tract infections. However, there is a paucity of data 
indicating that these resistance trends are translating 
into in vivo clinical failures.34x35 
The recommendations for treating outpatients and 
hospitalized patients are outlined in Table 2. Suitable 
empirical agents for CAP include a macrolide, 
doxycycline for children aged 8 years or older, or an oral 
beta-lactam with good activity against pneumococci. 
Regimens for hospitalized patients with CAP should 
include an intravenous beta-lactam. The DRSPTWG 
report proposes that, in order to limit the emergence of 
fluoroquinolone-resistant strains of S. pneumoniae, these 
agents should only be used if other therapeutic options 
have failed, if the patient is allergic to other agents, or 
if the strain of S. pneumoniae is highly drug-resistant 
(MIC=4 mg/L). 
CONCLUSION 
The prevalence of drug-resistant S. pneumoniae is 
increasing but varies considerably throughout the world. 
The clinical significance of this resistance is poorly 
defined, especially in relation to the treatment of 
pneumococcal lung disease. There is clear evidence that 
PRSP causing meningitis fail to respond to conven- 
tional management, while high-level resistance to 
macrolides is beginning to be reported as a cause of 
failure in pneumococcal pneumonia. Unless there is a 
dramatic change in the antibiotic-prescribing habits of 
physicians and other health care workers, it is unlikely 
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that this upward trend in antibiotic resistance will 
continue. At present, the preferred treatment of pneu- 
mococcal pneumonia continues to be penicillin 
(benzylpenicillin or amoxicillin). Empirical use of other 
agents such as macrolides and doxycycline still has a role 
in the community management of nonsevere CAP How- 
ever, pneumooccal meningitis in area with an incidence 
of high resistance now requires a third-generation 
cephalosporin, either alone or in combination with 
vancomycin. Once the results of culture and suscepti- 
bility testing are available, treatment can be modified. 
For the newer agents, such as meropenem and respira- 
tory fluroquinolone, more information on dose and 
duration of therapy is urgently required. The role and 
position of conjugate pneumococcal vaccine should be 
rapidly defined and could contribute significantly to the 
management of PRSP infection through prevention. 
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